All systems operational
Q3 2023

Strategic priorities for hematopoietic stem cell transplantation in the EMRO region

Syed Osman Ahmed · Riad El Fakih · Alaa Elhaddad · Amir Ali Hamidieh · Abdulghani Altbakhi · Qamar-Un-Nisa Chaudhry · Ali Bazarbachi · Salman Adil · Murtadha Al-khabori · Tarek Ben Othman · Javid Gaziev · Mohamad Khalaf · Salem Alshammeri · Sultan Alotaibi · Mohammed Alshahrani · Mohamed Amine Bekadja · Ahmad Ibrahim · Adel Mohammed Al-Wahadneh · Muna Altarshi · Ahmad Alsaeed · Abdellah Madani · Miguel Abboud · Husam Abujazar · Mohamad Bakr · Ibraheem Abosoudah · Jean El Cheikh · Ahlam Almasari · Feras Alfraih · Helen Bald
10.1016/j.hemonc.2021.09.006 391 Views 12 Citations
12
Citations
391
Views
Abstract

The World Health Organization-designated Eastern Mediterranean region (EMRO) consists of 22 countries in North Africa and Western Asia with a collective population of over 679 million. The area comprises some of the wealthiest countries per capita income and some of the poorest. The population structure is also unique and contrasts with western countries, with a much younger population. The region sits in the heart of the thalassemia belt. Many countries have a significant prevalence of sickle cell disease, and cancer is on the rise in the region. Therefore, the strategic priorities for the growth and development of hematopoietic stem cell transplantation (HSCT) differ from country to country based on resources, healthcare challenges, and prevalent infrastructure. Thirty-one reporting teams to the Eastern Mediterranean Blood and Marrow Transplantation Group have active HSCT programs in 12 countries; allogeneic transplants outnumber autologous transplants, and the proportion of allotransplants for non-malignant conditions is higher in the EMRO region than in Western Europe and North America. The vast majority (99%) of allotransplants are from matched related donors. Matched unrelated donors and other alternate donor transplants are underutilized. The chance of finding a matched related donor for allografts is higher, with a significant chance of finding matched donors among non-sibling related donors. Reasons for relatively lower rates of transplants compared with other countries are multifactorial. Capacity building, development of newer centers, innovative funding, and better utilization of information technology are required to make transplantation as an accessible modality to more patients. Cost-effectiveness and cost-containment, regulation, and ensuring quality will all be priorities in planning HSCT development in the region.

Cite this Article (APA)
Syed, O. A., Riad, E. F., Alaa, E., Amir, A. H., Abdulghani, A., Qamar-Un-Nisa, C., Ali, B., Salman, A., Murtadha, A., Tarek, B. O., Javid, G., Mohamad, K., Salem, A., Sultan, A., Mohammed, A., Mohamed, A. B., Ahmad, I., Adel, M. A., Muna, A., Ahmad, A., Abdellah, M., Miguel, A., Husam, A., Mohamad, B., Ibraheem, A., Jean, E. C., Ahlam, A., Feras, A., Helen, B. (2023). Strategic priorities for hematopoietic stem cell transplantation in the EMRO region. Hematology/Oncology and Stem Cell Therapy. https://doi.org/10.1016/j.hemonc.2021.09.006
Related Papers
The Risk and Prognosis of COVID-19 Infection in Cancer Patients
Ghada M. ElGohary; Shahrukh Hashmi; Jan Styczynski; Mohamed A. Kharfan-Dabaja; R · 2022
80
cites
398
Molecular mediators of breast cancer metastasis
Ragini Yeeravalli; Amitava Das · 2021
39
cites
388
Venetoclax and decitabine for treatment of relapsed T-cell acute lymphoblastic leukemia
Nosha Farhadfar; Ying Li; William S. May; Carolyn Brooke Adams · 2021
38
cites
392
Acute upper limb ischemia in a patient with COVID-19
Parminder Kaur; Firas Qaqa; Amr Ramahi; Yezin Shamoon; Monisha Singhal; Fayez Sh · 2021
35
cites
389
Access
View Full Text via DOI
Published in
ISSN 1658-3876
Quartile Q3
AMS Score 72
Field Medicine & Health Sciences
Publisher Elsevier / King Faisal Specialist H
Country 🇸🇦 Saudi Arabia
View Journal Profile →
Authors
Q
Qamar-Un-Nisa Chaudhry
J
Jean El Cheikh
Publication Details
Year 2023
Language English
Added 28 Jul 2026